



Curriculum Vitae

Personal information **Alessia Pochesci**

Work experience

Current position

- March 2021 - present: Responsible Physician of the Clinical Research Centre, Centre Hospitalier de Luxembourg (Luxembourg)

- March 2021 - present: Clinical Trial Coordinator, Luxembourg Institut of Health (Luxembourg)

Past Positions:

- January 2020 - February 2021: Clinical Research Physician, EORTC (Belgium)

- January 2018 - December 2019: junior Clinical Research Physician, EORTC (Belgium)

- August 2016 - December 2017: Medical Oncologist, Istituto Europeo di Oncologia - IEO (Italy)

- February 2015 - July 2016: Medical Oncology Trainee, Istituto Europeo di Oncologia - IEO (Italy)

- June 2011 - January 2015: Medical Oncology Trainee, Sapienza-University of Rome / Policlinico Umberto I (Italy)

Education and training

- June 2011 - July 2016: Medical Oncology Degree, Sapienza-University of Rome (Italy)

- October 2004 - July 2010: Medical Doctor Degree, Sapienza-University of Rome (Italy)

Additional information

Publications

Peters S, Danson S, Ejedepang D, Dafni U, Hasan B, Radcliffe HS, Bustin F, Crequit J, Coate L, Guillot M, Surmont V, Rauch D, Rudzki J, O'Mahony D, Barneto Aranda I, Scherz A, Tsourti Z, Roschitzki-Voser H, **Pochesci A**, Demonty G, Stahel RA, O'Brien M. Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials. *Lung Cancer*. 2021 Nov; 161: 76-85. doi: 10.1016/j.lungcan.2021.09.002. Epub 2021 Sep 9. PMID: 34543941.

J.Z. Musoro, S.C. Sodergren, C. Coens, **A. Pochesci**, M. Terada, M.T. King, M.Ag. Sprangers, M. Groenvold, K. Cocks, G. Velikova, H H. Flechtner, A. Bottomley. Minimally important differences for interpreting the EORTC QLQ C30 in advanced colorectal cancer patients treated with chemotherapy". *Colorectal Dis*. 2020 Aug 7. doi: 10.1111/codi.15295. Online ahead of print.

Peters S., Danson S., Hasan B., Dafni U., Reinmuth N., Majem M., Tournoy K.G., Mark M.T., Pless M., Cobo M., Rodriguez Abreu D., Falchero L., Moran T., Ortega Granados A.L., Monnet I., Mohorcic K., Massutí Sureda B., Betticher D., Demedts I., Macias J.A., Cuffe S., Luciani A., Garcia Sanchez J., Curioni Fontecedro A., Gautschi O., Price G., Coate L., von Moos R., Zielinski C., Provencio M., Menis J., Ruepp B., **Pochesci A.**, Roschitzki Voser H., Besse B., Rabaglio M., O'Brien M.E.R., Stahel R.A. "A randomised open label phase III trial evaluating the addition of denosumab to standard first line treatment in advanced NSCLC the ETOP and EORTC SPLENDOUR trial". *J Thorac Oncol*. 2020 Jun 18; doi: 10.1016/j.jtho.20 20.06.011. Online ahead of print.

Levy A., Hendriks L.E.L., Berghmans T., Faivre Finn C., Giaj Levra M., Giaj Levra N., Hasan B., **Pochesci A.**, Girard N.N., Greillier L.L., Lantuéjoul S.S., Edwards J.J., O'Brien M.M., Reck M.M., Besse B.B., Novello S.S., Dingemans A.M.C. EORTC Lung Cancer Group (EORTC LCG) LCG). EORTC Lung Cancer Group Survey on the

Definition of NSCLC Synchronous Oligometastatic Disease”. Eur J Cancer. 2019; 122: 109-114

Passaro A., Prelaj A., **Pochesci A.**, Spitaleri G., Rossi G., Del Signore E., Catania C., de Marinis F. “Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients”. Drugs of today. 2017; 53: 435-446

Rampinelli C., Spitaleri G., Passaro A., **Pochesci A.**, Ancona E., de Marinis F. “Lung tissue injury as atypical response to nivolumab in NSCLC”. Am J Respir Crit Care Med. 2017; 196(10):1349-1350.

Passaro A., Guerini-Rocco E., **Pochesci A.**, Vacirca D., Spitaleri G., Catania C.M., Rappa A., Barberis M., de Marinis F. “Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment”. Pharmacol Res 2017; 117: 406 – 415.

Passaro A., Lazzari C., Karachaliou N., Spitaleri G., **Pochesci A.**, Catania C., Rosell R., de Marinis F. “Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice”. Onco Targets Ther. 2016; 9: 6361 – 6376.

Passaro A., **Pochesci A.**, Spitaleri G., Catania C., Noberasco C., Del Signore E., de Marinis F. “Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data”. Expert Rev Clin Pharmacol. 2016; Sep 20: 1 – 6.

Pochesci A., Passaro A., Catania C., Noberasco G., Del Signore E., Spitaleri G., de Marinis F. “Immunotherapy in non-small cell lung cancer: evolution of knowledge and clinical advances”. Recenti Prog Med. 2016; 107: 186 – 192.

Passaro A., **Pochesci A.**, Spitaleri G., Catania C., Noberasco C., Del Signore E., de Marinis F. “Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?” J Thorac Dis. 2016; 8: E217 – E220.

Passaro A., Alesini D., **Pochesci A.**, Cortesi E. “Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer”. Anticancer Agents Med Chem. 2014; 14: 646 – 650.

ABSTRACT:

ESMO Congress 2021 September 16 – 21, 2021

N Girard, S Ponce Aix, S Cedres, T Berghmans, S Burgers, AC Toffart, S Popat, A Janssens, R Gervais, M Hochstenbag, M Silva, I Burger, H Prosch, RA Stahel, AS Govaerts, **A Pochesci**, A Neven, S Peters. LBA66 Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOOTHYM phase II trial. Annals of Oncology 2021, 32 (suppl 5): S1342

Selected as Proffered Paper at ESMO Congress 2021

ESMO Virtual Congress 2020 September 19 – 21, 2020

B. Besse, J. Menis, P. Bironzo, R. Gervais, L. Greillier, I. Monnet, L. Livi, R. Young, C. Decroisette, N. Cloarec, G. Robinet, R. Schott, R. Califano, F. De Marinis, G.L. Banna, M. Mauer, **A. Pochesci**, B. Hasan, T. Berghmans, A.C. Dingemans. LBA85 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer. Annals of Oncology 2020, 31 (suppl 4): S1142-S1215.

Selected as Mini-Oral for presentation during ESMO Virtual Congress 2020

26th annual conference of the international society for quality of life research, San Diego (CA), USA.

Musoro J., Coens C., King M., Sprangers M., Groenvold M., Cocks K., Velikova G., Singer S., Oosting S., Brandberg Y., Cardoso F., **Pochesci A.**, Terada M., Stelmes J.J., Frederic F., Katarzyna P., Reijneveld J., Dirven L., Taphoorn M., Greimel E., Nordi A., van Dorst E., Bottomley A. Establishing anchor based minimally important differences (MID) for the EORTC QLQ C30 scales across multiple cancer sites. Qual Life Res 2019; 28 (Suppl 1): B203.6.

ABSTRACT P1.06.06: Barcelona 2019 World Conference on Lung Cancer, September 7-10, 2019

EORTC 1205: Randomized study of pleurectomy/decortication (P/D) preceded or followed by chemotherapy in malignant pleural mesothelioma J. Van Meerbeek, P. Van Schil, V. Surmont, R. Gaafar, R. Cornelissen, B. Hasan, **A. Pochesci**, A. Maat, P. Baas, F. Vermassen. J Thorac Oncol 14 (10), S479

ABSTRACT MA08.02: Barcelona 2019 World Conference on Lung Cancer, September 7-10, 2019

“Durvalumab impact in the treatment strategy of stage III non small cell lung cancer (NSCLC): an EORTC young investigator Lung Cancer Group survey”. M. Gij Levra, J. Benet, B. Hasan, T. Berg hmans, A. Bruni, A.M. Dingemans, N. Gij Levra, J. Edwards, C. Faivre Finn, N. Girard, E. Gobbini, L. Greiller, L. Hendriks, S. Lantuejoul, A. Levy, S. Novello, M. O Brien, M. Reck, **A. Pochesci**, J. Menis, Besse. J Thorac Oncol 14 (10), S277 S278.

16th Annual ENETS Conference; Barcelona March 6-08, 2019

TELEFIRST |First line Lanreotide(LAN) + Telotristat ethyl(TE) /Placebo(PBO) in Patients(pts) with Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) with Highly Functioning Carcinoid Syndrome(CS): Randomized Phase III Trial. Lamarca A, Farro G, Barriuso J, Ramage J, Manoharan P, Dobson R, **Pochesci A**, Murielle M, Govaerts AS, Valle JW.

ABSTRACT 2635: Washington, DC, AACR Annual Meeting 2017; April 1-5, 2017.

“Baseline myeloid-derived suppressor cell and eosinophil cell counts predict clinical efficacy in patients with non-small cell lung cancer (NSCLC) treated with nivolumab in second line”

Mancuso P., Passaro A., Labanca V., Gandini S., Spitaleri G., Guerini E., Barberis M., Noberasco C., Del Signore E., **Pochesci A.**, Catania C., de Marinis F., Bertolini F. Cancer Research 2017, vol 77 (suppl 13): 2635.

ABSTRACT P2. 01-044: WIEN, 17th IASLC World Conference on Lung Cancer, December 4-7, 2016

“Baseline peripheral blood cell subsets associated with survival outcomes in advanced NSCLC treated with Nivolumab in second line setting”

A. Passaro, P. Mancuso, V. Labanca, G. Spitaleri, E. Guerini-Rocco, M. Barberis, S. Gandini, C. Noberasco, E. Del Signore, C. Catania, **A. Pochesci**, F. Bertolini, F. de Marinis. J Thorac Oncol 2017, vol 12 S812.

ABSTRACT E14: MILAN, XV NATIONAL CONGRESS AIOM, October 11-13, 2013
“Granulocyte colony stimulating factor (G-CSF) in the prevention of febrile neutropenia (FN) in breast cancer (BC) patients: the fewer the better”

Risi E., Morano F., Campennì G., Palleschi M., **Pochesci A.**, Mosillo C., Pellegrino D., Palazzo A., Trenta P., Urbano F., Manai C., Giovannoni S., Lo Russo V., Cortesi E.
Published by Tumori 2013 **Selected for Poster Presentation XV National Congress AIOM, Milan 2013**

ABSTRACT 71PD: Lugano, European Multidisciplinary Conference in Thoracic Oncology (EMCTO), May 9-11, 2013

“Reversible epidermal growth factor receptor tyrosine kinases inhibitors (REGFR-TKIS), erlotinib or gefitinib, compared to chemotherapy (CHT) in previously treated metastatic non small cell lung cancer (NSCLC) patients (PTS): a meta-analysis.

A. Pochesci, P. Trenta, R. Iacovelli, M. Palleschi, A. A. Prete, V. Magri, C. Mosillo, D. Pellegrino, A. De Benedetto, E. Cortesi.

Lung Cancer vol 80 S32-33 **Selected for Poster Discussion EMCTO, Lugano 2013**

ABSTRACT F14: ROME, XIV NATIONAL CONGRESS AIOM, October 27-29, 2012
“Benefit of post-docetaxel treatment in castration resistant prostate cancer patients with poor performance status”

Altavilla A., Iacovelli R., Truscilli K., Morano F., Risi E., **Pochesci A.**, Alesini D., Palazzo A., Pellegrino D., Cortesi E.

Published by Tumori 2012 **Selected for Poster Presentation XIV National Congress**

AIOM, Rome 2012

ABSTRACT F3: ROME, XIV NATIONAL CONGRESS AIOM, October 27-29, 2012
“Antiangiogenic agents are ineffective to increase complete response rate in mRCC. A meta-analysis”

Alesini A., Altavilla A., Passaro A., Campennì G.M., Iacovelli R., Palleschi M., **Pochesci A.**, Giovannoni S., Trenta P., Cortesi E.

Published by Tumori 2012. **Selected for Oral Presentation XIV National Congress AIOM, Rome 2012**

ABSTRACT A42: ROME, XIV NATIONAL CONGRESS AIOM, October 27-29, 2012

“First-line polychemotherapy is more effective than gemcitabine in unselected patients affected by advanced pancreatic carcinoma”

Palleschi M., **Pochesci A.**, Alesini D. Passaro A., Giovannoni S., Modica D. Lo Russo V., Pellegrino D., Iacovelli R., Mezi S.

Published by Tumori 2012

ABSTRACT B47: ROME, XIV NATIONAL CONGRESS AIOM, October 27-29, 2012.

“Time to skin toxicity is related to response rate in patients with colorectal cancer treated with cetuximab: a retrospective analysis”.

Pochesci A., Palleschi M., Alesini D., Manai C., Modica D., Altavilla A., Prete A., Magri V., Iacovelli R., Cortesi E.

Published by Tumori 2012. **Selected for Poster Presentation XIV National Congress AIOM, Rome 2012**

“Efficacy and safety of pemetrexed as second-line treatment in elderly patients with advanced non squamous non small lung cancer: a retrospective analysis”.

A.Passaro, **A.Pochesci**, M.Palleschi, A.Pellegrino, M.A.Fabbri, F.Urbano, V.Gentile, C.Manai, I.Pavese, E.Cortesi.

J Thorac Oncol, vol 7 n 6 suppl 1, June 2012

Abstract 66: 22nd Annual Meeting of the Italian Society of Uro-Oncology, Bologna, June 13-15, 2012

“Benefit of post-docetaxel treatment in castration resistant prostate cancer patients with poor performance status”

A. Altavilla, R. Iacovelli, K. Truscetti, F. Morano, E. Risi, **A. Pochesci**, V. Lo Russo, F. Urbano, A. Palazzo, E. Cortesi.

Published by Anticancer Res 2012, 32: 1843-1966

Abstract E3: Bologna, XIII NATIONAL CONGRESS AIOM November 5-7, 2011

“The role of bevacizumab (B) in the maintenance treatment after chemotherapy (CT) for metastatic colorectal cancer (MCRC) patients (PTS): an Italian multicenter retrospective analysis”.

Moscetti L., Fabbri A., Sperduti I., **Pochesci A.**, Alesini D., Gemma D., Grande R., Pavese I., Franco D., Ruggeri E.

Published by Tumori 2011 October, volume 11 Abstract E3. **Selected for Poster and Oral Presentation XIII National Congress AIOM, Bologna 2011**

J ENDOCRINOL INVEST 34 suppl 3 2011

“Thyrotoxicosis during sunitinib therapy: a case report”

Grani G., Paone L., Coletta I., Di Fiore A., Coccaro C., Alesini D., Modica D., **Pochesci A.**, Palleschi M., Truscetti K.

Abstract 79P: IMPAKT BREAST CANCER CONFERENCE Bruxelles, May 5-6-7, 2011

“Mesenchymal markers in circulating tumour cells: prognostic significance in breast cancer patients”

E. Risi, C. Raimondi, C. Nicolazzo, A. Palazzo, M. Palleschi, **A. Pochesci**, A. Petracca, G. Naso, E. Cortesi, P. Gazzaniga

Published by Annals of Oncology 2011 May, volume 22 (suppl 2): ii42 Abstract 79P

Abstract H28: ROME, XII NATIONAL CONGRESS AIOM November 6-8, 2010
“Safety and toxicity of biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (folfox--txt) in gastric cancer patients according to age and performance status: a retrospective, monoinstitutional study”

D. Conte, M.L. Mancini, M. Mazzoli, F. Morano, A. Passaro, A. Altavilla, D. Modica, D. Alesini, **A. Pochesci**, M. Palleschi, F. Brunini, S. Mezi

Published by Tumori 2010 October, volume 10 Abstract H28. **Selected for Poster Presentation XII National Congress AIOM, Rome 2010**

Abstract D28: ROME, XII NATIONAL CONGRESS AIOM November 6-8, 2010

“Analysis of elderly population treated with erlotinib for non small cell lung cancer (Nsclc)”

Iacovelli R., Palazzo A., **Pochesci A.**, Palleschi M., Campennì G., Risi E., Pellegrino A., Tuzi A., Raimondi C., Mezi S., Cortesi E

Published by Tumori 2010 October, volume 10 Abstract D28. **Selected for Poster Presentation XII National Congress AIOM, Rome 2010**

[Projects](#)

[Memberships](#)

[Other Relevant Information](#)